Evaluating BHV-7000 for treating refractory focal epilepsy in adults
Official title: A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Run by Biohaven Pharmaceuticals, Inc. · NCT06309966 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new drug called BHV-7000 to see if it can help adults with hard-to-treat focal epilepsy who haven't found relief from other treatments.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 390 (estimated) |
| Sponsor | Biohaven Pharmaceuticals, Inc. Industry-sponsored |
| Locations | 174 sites (Birmingham, Alabama and 173 other locations) |
| Trial ID | NCT06309966 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with a diagnosis of refractory focal onset epilepsy and a history of inadequate response to multiple anti-seizure medications.
✕Probably not a fit
Patients with a history of status epilepticus or those who do not meet the criteria for refractory epilepsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the effectiveness and safety of BHV-7000 in adults suffering from refractory focal onset epilepsy. Participants will receive either the investigational drug or a placebo, and their responses will be monitored over time. The study includes individuals aged 18 to 75 who have a history of focal seizures and have not achieved seizure freedom despite previous treatments. The goal is to determine if BHV-7000 can provide a new therapeutic option for this challenging condition.
Why it matters
Potential benefit: If successful, this treatment could offer a new hope for patients with refractory focal epilepsy who have limited options.
How similar studies have gone: Other studies have explored treatments for refractory epilepsy, but the specific approach with BHV-7000 is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: 1. Male and Female participants 18 to 75 years of age at time of consent. 2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria. a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures with clinically observable signs and/or symptoms iii. Focal to bilateral tonic-clonic seizures 3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. 4. Ability to keep accurate seizure diaries 5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total Key Exclusion Criteria: 1. History of status epilepticus (convulsive status epilepticus for \> 5 minutes or focal status epilepticus with impaired consciousness for \> 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure. 2. History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase. 3. Resection neurosurgery for seizures \<4 months prior to the screening visit. 4. Radiosurgery performed \<2 years prior to the screening visit. 5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms. 6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator
Where it's running
-
Onyx Clinical Trials
Peoria, Arizona, United States Recruiting -
Xenoscience, Inc.
Phoenix, Arizona, United States Recruiting -
University of Arizona / Banner University Medical Center Phoenix
Phoenix, Arizona, United States Recruiting -
ARENSIA Exploratory Medicine
Phoenix, Arizona, United States Recruiting -
Clinical Trials, Inc.
Little Rock, Arkansas, United States Recruiting -
Tri Valley Neurology Medical Associates, Inc.
Mission Hills, California, United States Recruiting
Show 44 more locations
-
Profound Research LLC
Poway, California, United States Recruiting -
UConn Health
Farmington, Connecticut, United States Recruiting -
Nova Clinical Research, LLC
Bradenton, Florida, United States Recruiting -
Las Mercedes Medical Research
Hialeah, Florida, United States Recruiting -
Coral Clinic Research
Homestead, Florida, United States Recruiting -
Y&L Advance Health Care, Inc d/b/a Elite Clinical Research
Miami, Florida, United States Recruiting -
Serenity Research Center
Miami, Florida, United States Recruiting -
Research Institute of Orlando
Orlando, Florida, United States Recruiting -
Comprehensive Neurology Clinic
Orlando, Florida, United States Recruiting -
Panhandle Research & Medical Clinic
Pensacola, Florida, United States Recruiting -
Knight Neurology
Rockledge, Florida, United States Recruiting -
Encore Medical Research of Weston LLC.
Weston, Florida, United States Recruiting -
Accelerated Clinical Trials, LLC
Peachtree Corners, Georgia, United States Recruiting -
Bluegrass Epilepsy Research
Lexington, Kentucky, United States Recruiting -
DelRicht Research
Baton Rouge, Louisiana, United States Recruiting -
Neurocare Of Louisiana
Covington, Louisiana, United States Recruiting -
University Medical Center New Orleans
New Orleans, Louisiana, United States Recruiting -
DelRicht Research
New Orleans, Louisiana, United States Recruiting -
LSU Health Shreveport
Shreveport, Louisiana, United States Recruiting -
Johns Hopkins University
Baltimore, Maryland, United States Recruiting -
Boston Clinical Trials
Boston, Massachusetts, United States Recruiting -
Boston Neuro Research
South Dartmouth, Massachusetts, United States Recruiting -
SRI International
Plymouth, Michigan, United States Recruiting -
University of Missouri Health Care
Columbia, Missouri, United States Recruiting -
Somnos Clinical Research
Lincoln, Nebraska, United States Recruiting -
Nereg
Hackensack, New Jersey, United States Recruiting -
Tekton Research
Marlboro, New Jersey, United States Recruiting -
Dent Neurosciences Research Center
Amherst, New York, United States Recruiting -
Northwell Health
Great Neck, New York, United States Recruiting -
NYU Langone Health
New York, New York, United States Recruiting -
Montefiore Medical Center
The Bronx, New York, United States Recruiting -
Premier Health
Dayton, Ohio, United States Recruiting -
Oregon Neurology Associates
Springfield, Oregon, United States Recruiting -
Ahn
Pittsburgh, Pennsylvania, United States Recruiting -
Musc
Charleston, South Carolina, United States Recruiting -
Le Bonheur Children's Hospital
Memphis, Tennessee, United States Recruiting -
Horizon Clinical Research Group
Cypress, Texas, United States Recruiting -
M3 Wake Research-Dallas
Dallas, Texas, United States Recruiting -
ANESC Research
El Paso, Texas, United States Recruiting -
UTHealth Houston
Houston, Texas, United States Recruiting -
Uthsc
Houston, Texas, United States Recruiting -
Stryde Research
Plano, Texas, United States Recruiting -
Intermountain Health
Murray, Utah, United States Recruiting -
Medstar Health Research Institute
McLean, Virginia, United States Recruiting
+124 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Chief Medical Officer
- Email: clinicaltrials@biohavenpharma.com
- Phone: 203-404-0410
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-density flexible microneuroelectrode mapping to guide epilepsy surgery
This study tests whether using high-density flexible microelectrocorticography during surgery helps guide the resection of the epileptogenic zone in people with drug-resistant focal epilepsy.
-
RAP-219 for adults with focal seizures
This study tests whether RAP-219 can reduce how often focal seizures happen in adults with focal epilepsy, compared with a placebo.
-
Spatial scene memory testing for people with temporal lobe epilepsy having surgery
This project tests whether a virtual tour memory task combined with brain recordings can show how adults with temporal lobe epilepsy recognize and recall places.
-
RAP-219 in adults with focal seizures
This study tests whether RAP-219 can safely reduce the number of focal seizures in adults with focal epilepsy compared with placebo.
-
Probenecid for cluster seizures during presurgical epilepsy monitoring
This trial tests whether probenecid can help control clusters of seizures in people with focal epilepsy during presurgical video-EEG monitoring.
-
Long-term daily CB03-154 treatment for focal epilepsy
This extension will try once-daily CB03-154 (up to 20 mg) in people with focal epilepsy who completed the prior Phase 2 study to see if it is safe, tolerated, and helps control seizures over up to two years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.